Randomized phase II trial with irinotecan as monotherapy compared to irinotecan and bevacizumab (BevIri) for patients with platinum resistant non-resectable esophagus-, cardia or gastric cancer
Read time: 1 mins
Last updated:2nd Nov 2012
To evaluate the efficacy of bevacizumab and irinotecan in combination compared to irinotecan alone in patients with esophagus, cardia or gastric cancer.
|Study start date||2012-11-02|